Business
Entera Bio Ltd Announces Interim Biomarker Data From Phase 2 Clinical Trial of EB613 and First Quarter 2020 Financial Results
‒ Statistically Significant One Month Increases in P1NP Biomarker from First 50% of Patients with Highest Dose of EB613 ‒‒ Company to Follow Patients in the
About this update from Entera Bio Ltd.
[{"type":"text","content":"‒ Statistically Significant One Month Increases in P1NP Biomarker from First 50% of Patients with Highest Dose of EB613 ‒‒ Company to Follow Patients in the Phase 2 Clinical Trial of EB613 through Six Months for Bone Mineral Density Data and Evaluate Additional Higher Doses of EB613 ‒‒ Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT ‒\n BOSTON and JERUSALEM, May 21, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced interim limited biomarker data from the ongoing Phase 2 clinical trial of EB613 in osteoporosis patients and results for the quarter ended March 31, 2020. The study demonstrated statistically significant effects on the P1NP biomarker after one month of treatment (p","length":1120,"tagName":"div"}]